Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,583,376
  • Shares Outstanding, K 5,554,834
  • Annual Sales, $ 51,750 M
  • Annual Income, $ 16,273 M
  • 60-Month Beta 0.74
  • Price/Sales 4.11
  • Price/Cash Flow 9.31
  • Price/Book 3.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.70
  • Number of Estimates 3
  • High Estimate 0.79
  • Low Estimate 0.60
  • Prior Year 0.75
  • Growth Rate Est. (year over year) -6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.52 +11.21%
on 07/13/20
39.45 -2.69%
on 07/29/20
+4.56 (+13.48%)
since 07/10/20
3-Month
31.61 +21.45%
on 06/26/20
39.45 -2.69%
on 07/29/20
+1.17 (+3.14%)
since 05/08/20
52-Week
27.88 +37.70%
on 03/23/20
40.97 -6.30%
on 01/24/20
+2.04 (+5.61%)
since 08/09/19

Most Recent Stories

More News
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

SNY : 50.91 (-1.16%)
DVAX : 7.79 (+0.13%)
PFE : 38.39 (-0.16%)
GILD : 68.51 (-1.21%)
MRNA : 72.01 (-2.82%)
LLY : 153.00 (+0.05%)
GSK : 40.94 (+0.37%)
AMGN : 238.17 (-1.05%)
ADPT : 37.60 (-1.62%)
BNTX : 73.95 (-3.96%)
Global Ocular Inflammation Treatment Market 2020 With COVID-19 Update, Industry Segmentation, CAGR Status, Leading Trends, and Forecast To 2026

A recent report provides crucial insights along with application based and forecast information in the Global Ocular Inflammation Treatment Market. The report provides a comprehensive analysis of key factors...

AKRX : 0.0900 (-51.01%)
ALIM : 6.65 (+5.39%)
AGN : 193.02 (+0.02%)
NVS : 82.39 (-0.63%)
PFE : 38.39 (-0.16%)
VRX.TO : 30.80 (-3.33%)
Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

JNJ : 148.03 (-0.38%)
PFE : 38.39 (-0.16%)
MRK : 80.91 (-0.14%)
LLY : 153.00 (+0.05%)
BMY : 61.82 (+1.31%)
PPH : 63.87 (+0.17%)
PJP : 66.50 (-0.33%)
IHE : 163.42 (-0.24%)
XPH : 44.58 (-0.34%)
FTXH : 24.50 (+0.16%)
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

PFE : 38.39 (-0.16%)
MRK : 80.91 (-0.14%)
BMY : 61.82 (+1.31%)
NKTR : 21.35 (-2.29%)
A sleepy North Carolina city flexes its logistics muscle

City checks off many of the distribution center site boxes.

CSX : 74.08 (+1.58%)
CBRE : 45.37 (+3.07%)
PFE : 38.39 (-0.16%)
GLW : 32.15 (+0.94%)
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing...

PFE : 38.39 (-0.16%)
Ocular Drug Delivery Technology Market Threats, Phenomenal Growth Prospects and Opportunities|Alimera Sciences Inc, Valeant Pharmaceuticals International Inc and Clearside Biomedical Inc

AGN : 193.02 (+0.02%)
CLSD : 1.7900 (+1.70%)
NVS : 82.39 (-0.63%)
OCUL : 8.46 (+3.05%)
PFE : 38.39 (-0.16%)
VRX.TO : 30.80 (-3.33%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020

and , /PRNewswire/ -ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate...

EPIX : 6.70 (-1.90%)
EPI.VN : 9.070 (+4.01%)
PFE : 38.39 (-0.16%)
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program

Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program

PFE : 38.39 (-0.16%)
ACHV : 11.13 (+1.27%)
Global Vaccines Industry Landscape 2020-2027: Increase in Incidence of Both Viral and Bacterial Infectious Diseases

, /PRNewswire/ -- The report has been added to offering.

CSLLY : 99.9200 (+1.49%)
DSNKY : 88.5728 (+0.29%)
MRK : 80.91 (-0.14%)
MTZPY : 18.6000 (-0.13%)
PFE : 38.39 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade PFE with:

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 38.84
1st Resistance Point 38.61
Last Price 38.39
1st Support Level 38.21
2nd Support Level 38.04

See More

52-Week High 40.97
Last Price 38.39
Fibonacci 61.8% 35.97
Fibonacci 50% 34.42
Fibonacci 38.2% 32.88
52-Week Low 27.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar